Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT05726864 is registered in ClinicalTrials.gov with Elicio Therapeutics as lead sponsor.

NCT NCT05726864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05726864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Lead sponsor
Elicio Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 14, 2023
Completion date
November 30, 2026
Enrollment
158 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, kras g12a, kras g12c, kras g12d, kras g12r, kras g12s, kras g12v, kras g13d, nras g12c, nras g12d, nras g12r, nras g12s, nras g12v, pancreatic ductal adenocarcinoma